← Back to patent-cliff list

YPS-345

Tier C — Watch / trade

YPS-345

-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type

Targets:Inflammation mediators

Indications (approved):Pulmonary fibrosis, Pneumonia

Regional status

US
-
EU
-
China
Phase II
2021-12-03
Japan
-

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of YPS-345?

Approved indications include: Pulmonary fibrosis, Pneumonia.

When does the YPS-345 patent expire?

No public expiry year is available for YPS-345 yet; this page updates once verified.

How do I get a quote for YPS-345 intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-10-21